Teva files for Ajovy approval in Japan, where it is changing strategy

30 July 2020

Israel-based Teva Pharmaceutical Industries (NYSE: TEVA) announced that its partner, Otsuka Pharmaceutical (TYO: 4578), has submitted an application to the Pharmaceuticals and Medical Devices Agency of Japan to obtain manufacturing and marketing approval in Japan for Ajovy (fremanezumab) injection for the preventive treatment of migraine.

“This is an exciting milestone that delivers on our global mission to improve patients’ lives by advancing potential new treatment options,” said Gianfranco Nazzi, executive vice president, international markets at Teva, adding: “Driven by the aspiration to bring high-value products to patients, we are pleased to be one step closer to making Ajovy available as a treatment option to patients in Japan living with migraine.”

Ajovy is under development in Japan by Otsuka as part of a May 2017 exclusive license agreement for development and sales of the drug in Japan, which generated an upfront payment of $50 million to Teva.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK